As we look forward into the remainder of 2026, the medical community is cautiously optimistic about the "Holy Grail" of oncology: the universal vaccine. Unlike personalized shots, which target a single patient’s mutations, universal vaccines target common proteins like MUC1 or hTERT that are found across 90% of all cancers. Phase II data released in mid-2026 suggests that a broad-spectrum...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Italiano
Romaian
Portuguese (Brazil)
china